个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy and Safety of Atezolizumab in Chinese Patients With Advanced Thymic Carcinoma: A Multicenter, Single-Arm Phase 2 Study

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Lu Shun[1] * ; Ma Xuezhen[2] ; Liu Lunxu[3] ; Li Qiang[4] ; Hu Jian[5] ; Wang Changli[6] ; He Jianxing[7] ; Hu Xiufeng[8] ; Chen Chun[9] ; Yang Zhenzhou[10] ; Hu Dandan[11] ; Shi Yanjun[11] ; Zhou Yi[11] ; Chen Mo[11] ;
机构： [1]Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: shunlu@sjtu.edu.cn. [2]Department of Oncology, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, China. [3]Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China. [4]Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, Sichuan, China. [5]Department of Thoracic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, China. [6]Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China. [7]Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China. [8]Department of Internal Medicine, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China. [9]Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China. [10]Department of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. [11]Medical Department, Shanghai Roche Pharmaceuticals Ltd., Shanghai, China.
出处：
DOI： 10.1016/j.cllc.2025.01.011
ISSN：

关键词： Objective response rate Programmed death ligand 1 inhibitor Atezolizumab Thymic carcinoma

摘要：
There are limited treatment options for thymic carcinoma. This study aimed to evaluate the efficacy and safety of atezolizumab for the treatment of advanced thymic carcinoma after failure with prior systemic therapy.Patients aged ≥ 18 years with advanced thymic carcinoma after failure with prior systemic therapy were enrolled at 10 medical centers in China. Atezolizumab 1200 mg was administered on Day 1 (baseline) every 3 weeks until unacceptable toxicity/loss of clinical benefit. The primary efficacy endpoint was the confirmed objective response rate in the full analysis set.Between 29 July 2020 and 28 December 2022, 34 patients enrolled (median age, 54.5 years), and 16 (47.1%) had received ≥ 2 prior lines of therapy. At the cut-off date (July 16, 2023), the median follow-up duration was 19.1 months. The confirmed objective response rate (ORR) was 14.7% (95% confidence interval, 5.0%-31.1%); disease control rate, 58.8%; median progression-free survival (PFS), 3.2 months; 24-month OS rate, 63.2%; Better ORR and PFS were observed in PD-L1-positive patients versus PD-L1-negative patients (40.0% vs. 0% and 7.4 vs. 1.5 months, respectively). No correlation was observed with TMB. The incidence of adverse events (AEs) was 94.1%; serious AEs, 26.5%; immune-related AEs, 29.4%; and AEs leading to drug withdrawal, 2.9%.In patients with advanced thymic carcinoma who had failed prior systemic therapy, atezolizumab was well-tolerated with a manageable toxicity profile and showed encouraging the antitumor activity, especially in patients with PD-L1-positive tumors.Copyright © 2025. Published by Elsevier Inc.

基金：
This study was funded by F. Hoffmann–La Roche Ltd. We thank Michelle Belanger, MD, of Edanz (www.edanz.com), for providing medical writing support, which was funded by F. Hoffmann– La Roche Ltd., in accordance with Good Publication Practice 2022 guidelines (http://www.ismpp.org/gpp-2022).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
无
最新[2023]版：
大类 | 3 区 医学
小类 | 4 区 肿瘤学
第一作者：
第一作者机构： [1]Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: shunlu@sjtu.edu.cn.
通讯作者：
推荐引用方式(GB/T 7714)：
Lu Shun,Ma Xuezhen,Liu Lunxu,et al.Efficacy and Safety of Atezolizumab in Chinese Patients With Advanced Thymic Carcinoma: A Multicenter, Single-Arm Phase 2 Study[J].Clinical Lung Cancer.2025,doi:10.1016/j.cllc.2025.01.011.
APA：
Lu Shun,Ma Xuezhen,Liu Lunxu,Li Qiang,Hu Jian...&Chen Mo.(2025).Efficacy and Safety of Atezolizumab in Chinese Patients With Advanced Thymic Carcinoma: A Multicenter, Single-Arm Phase 2 Study.Clinical Lung Cancer,,
MLA：
Lu Shun,et al."Efficacy and Safety of Atezolizumab in Chinese Patients With Advanced Thymic Carcinoma: A Multicenter, Single-Arm Phase 2 Study".Clinical Lung Cancer .(2025)

相关文献

[1]PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma [2]Clinical benefit and safety associated with mRNA vaccines for advanced solid tumors: A meta-analysis [3]Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer [4]A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma [5]A phase II trial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma [6]Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors [7]Intrathyroid thymic carcinoma: clinicopathological features and whole exome sequencing analysis [8]Long-Term Survival after Surgical Treatment for Thymic Carcinoma [9]Intrathyroid thymic carcinoma: clinicopathological features and whole exome sequencing analysis [10]The IASLC/ITMIG thymic epithelial tumors staging project: Proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors(Open Access)

资源点击量：54033 今日访问量：0 总访问量：4614 更新日期：2025-03-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号